BIOLASE, Inc. (BIOLASE) is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers. It offers two categories of laser system products: WaterLase (all-tissue) systems and Diode (soft tissue) systems. Its brand, WaterLase, uses a combination of water and laser energy to perform procedures performed using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. It also offers its Diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. Its Waterlase and Diode systems use disposable laser tips of differing sizes and shapes depending on the procedures being performed.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Advanced Medical Equipment & Technology
- Sub-Industry: N/A
- Symbol: NASDAQ:BIOL
- CUSIP: N/A
- Web: www.biolase.com
Capitalization:- Market Cap: $41.03 million
- Outstanding Shares: 75,976,000
Average Prices:- 50 Day Moving Avg: $0.61
- 200 Day Moving Avg: $1.01
- 52 Week Range: $0.48 - $1.98
P/E:- Trailing P/E Ratio: N/A
- P/E Growth: -0.1800
Sales & Book Value:- Annual Revenue: $50.48 million
- Price / Sales: 0.85
- Book Value: $0.33 per share
- Price / Book: 1.70
Profitability:- EBIDTA: ($14,680,000.00)
- Net Margins: -31.64%
- Return on Equity: -64.44%
- Return on Assets: -35.66%
Debt:- Current Ratio: 2.21%
- Quick Ratio: 1.23%
Misc:- Average Volume: 143,783 shs.
- Beta: 2.26
- Short Ratio: 16.73
Frequently Asked Questions for Biolase (NASDAQ:BIOL)
What is Biolase's stock symbol?
Biolase trades on the NASDAQ under the ticker symbol "BIOL."
How were Biolase's earnings last quarter?
Biolase, Inc. (NASDAQ:BIOL) issued its quarterly earnings results on Monday, August, 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by $0.04. The business earned $12.61 million during the quarter. Biolase had a negative return on equity of 64.44% and a negative net margin of 31.64%. View Biolase's Earnings History.
When will Biolase make its next earnings announcement?
Where is Biolase's stock going? Where will Biolase's stock price be in 2017?
1 brokers have issued 12 month price objectives for Biolase's stock. Their forecasts range from $2.50 to $2.50. On average, they anticipate Biolase's share price to reach $2.50 in the next year. View Analyst Ratings for Biolase.
Who are some of Biolase's key competitors?
Some companies that are related to Biolase include Digirad Corporation (DRAD), Electromed (ELMD), Presbia PLC (LENS), Luna Innovations Incorporated (LUNA), Invivo Therapeutics Holdings Corp (NVIV), EnteroMedics (ETRM), Advanced Oncotherapy PLC (AVO), Dextera Surgical (DXTR), Xtant Medical Holdings (XTNT), Dynatronics Corporation (DYNT), PhotoMedex (PHMD), Alliance HealthCare Services (AIQ), BIOLASE (BLTI), Cynosure (CYNO), Derma Sciences (DSCI), Hansen Medical (HNSN), Lifeline Scientific (LSIC) and Mindray Medical International Ltd (MR).
Who are Biolase's key executives?
Biolase's management team includes the folowing people:
- Jonathan T. Lord M.D., Chairman of the Board
- Harold C. Flynn Jr., President, Chief Executive Officer
- Brendan O'Connell, Vice President - Finance and Corporate Controller
- Holger Arens, Vice President, Managing Director of Europe, the Middle East and Africa
- James D. Surek, Vice President - Sales, Americas
- Michael Roux, Vice President of Marketing
- Matthew Wilson, Vice President of Human Resources
- Samuel B. Low, Vice President - Dental and Clinical Affairs, Chief Dental Officer
- George W. Bickerstaff III, Director
- Paul N. Clark, Director
Who owns Biolase stock?
Biolase's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (2.23%), Birchview Capital LP (1.90%), Granite Investment Partners LLC (1.41%), Trellus Management Company LLC (0.52%), Teton Advisors Inc. (0.50%) and California Public Employees Retirement System (0.18%). Company insiders that own Biolase stock include David C Dreyer, Jack W Schuler, Larry N Feinberg and Paul N Clark. View Institutional Ownership Trends for Biolase.
Who sold Biolase stock? Who is selling Biolase stock?
Biolase's stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Granite Investment Partners LLC and Princeton Capital Management Inc.. View Insider Buying and Selling for Biolase.
Who bought Biolase stock? Who is buying Biolase stock?
Biolase's stock was bought by a variety of institutional investors in the last quarter, including Trellus Management Company LLC. Company insiders that have bought Biolase stock in the last two years include David C Dreyer, Jack W Schuler, Larry N Feinberg and Paul N Clark. View Insider Buying and Selling for Biolase.
How do I buy Biolase stock?
Shares of Biolase can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Biolase's stock price today?
One share of Biolase stock can currently be purchased for approximately $0.57.
MarketBeat Community Rating for Biolase (NASDAQ BIOL)MarketBeat's community ratings are surveys of what our community members think about Biolase and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Biolase (NASDAQ:BIOL) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Buy Rating |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $2.50 (341.46% upside) |
Analysts' Ratings History for Biolase (NASDAQ:BIOL)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 4/25/2017 | Singular Research | Initiated Coverage | Buy | $2.50 | Low |  |
(Data available from 9/21/2015 forward)
Earnings History for Biolase (NASDAQ:BIOL)Earnings History by Quarter for Biolase (NASDAQ BIOL)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/6/2017 | | ($0.04) | | | | | N/A | |
| 8/7/2017 | Q2 2017 | ($0.02) | ($0.06) | | $12.61 million | View | Listen | |
| 5/3/2017 | Q1 2017 | ($0.03) | ($0.06) | | $10.87 million | View | Listen | |
| 3/8/2017 | Q4 2016 | $0.02 | ($0.06) | | $13.76 million | View | Listen | |
| 11/8/2016 | Q316 | ($0.02) | ($0.05) | $12.40 million | $13.20 million | View | Listen | |
| 5/9/2016 | Q116 | ($0.03) | ($0.07) | $11.90 million | $11.00 million | View | N/A | |
| 3/9/2016 | Q415 | ($0.09) | ($0.04) | $13.90 million | $14.50 million | View | N/A | |
| 11/4/2015 | Q315 | ($0.08) | ($0.09) | $1.50 million | $11.20 million | View | N/A | |
| 11/4/2014 | Q314 | ($0.09) | ($0.08) | $11.70 million | $12.70 million | View | N/A | |
| 8/7/2014 | Q214 | ($0.08) | ($0.17) | $12.97 million | $10.20 million | View | N/A | |
| 5/12/2014 | Q114 | ($0.05) | ($0.11) | $13.29 million | $11.50 million | View | N/A | |
| 3/5/2014 | Q413 | ($0.04) | ($0.04) | $15.67 million | $15.20 million | View | N/A | |
| 11/5/2013 | Q313 | ($0.05) | ($0.10) | $16.42 million | $12.30 million | View | N/A | |
| 8/7/2013 | Q2 2013 | ($0.04) | ($0.06) | $15.69 million | $14.20 million | View | Listen | |
| 5/7/2013 | Q1 2013 | ($0.01) | ($0.06) | $14.48 million | $14.60 million | View | N/A | |
| 3/6/2013 | Q4 2012 | | $0.05 | $18.03 million | $19.10 million | View | Listen | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Biolase (NASDAQ:BIOL)No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Biolase (NASDAQ:BIOL)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Biolase (NASDAQ:BIOL)Insider Ownership Percentage: 7.10%
Institutional Ownership Percentage: 37.34%
Insider Trades by Quarter for Biolase (NASDAQ:BIOL)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 2/18/2016 | Jack W Schuler | Major Shareholder | Buy | 500 | $0.80 | $400.00 | |
| 2/17/2016 | Jack W Schuler | Major Shareholder | Buy | 4,100 | $0.80 | $3,280.00 | |
| 2/12/2016 | Jack W Schuler | Major Shareholder | Buy | 19,080 | $0.76 | $14,500.80 | |
| 2/10/2016 | Jack W Schuler | Major Shareholder | Buy | 67,213 | $0.78 | $52,426.14 | |
| 1/25/2016 | Jack W Schuler | Major Shareholder | Buy | 1,400 | $0.80 | $1,120.00 | |
| 1/22/2016 | Jack W Schuler | Major Shareholder | Buy | 6,670 | $0.78 | $5,202.60 | |
| 1/20/2016 | Jack W Schuler | Major Shareholder | Buy | 24,200 | $0.75 | $18,150.00 | |
| 12/28/2015 | Jack W Schuler | Major Shareholder | Buy | 18,350 | $0.79 | $14,496.50 | |
| 12/24/2015 | Jack W Schuler | Major Shareholder | Buy | 41,900 | $0.76 | $31,844.00 | |
| 12/22/2015 | Jack W Schuler | Major Shareholder | Buy | 87,200 | $0.74 | $64,528.00 | |
| 12/21/2015 | Jack W Schuler | Major Shareholder | Buy | 127,892 | $0.73 | $93,361.16 | |
| 12/17/2015 | Jack W Schuler | Major Shareholder | Buy | 34,158 | $0.70 | $23,910.60 | |
| 11/11/2015 | Larry N Feinberg | Major Shareholder | Buy | 54,800 | $0.79 | $43,292.00 | |
| 11/10/2015 | Paul N Clark | Director | Buy | 134,579 | $0.75 | $100,934.25 | |
| 9/24/2015 | David C Dreyer | CFO | Buy | 5,000 | $1.20 | $6,000.00 | |
| 9/22/2015 | David C Dreyer | CFO | Buy | 5,000 | $1.37 | $6,850.00 | |
| 9/17/2015 | David C Dreyer | CFO | Buy | 10,000 | $1.45 | $14,500.00 | |
| 11/3/2014 | Jeffrey M Nugent | CEO | Buy | 40,465 | $2.39 | $96,711.35 | |
| 11/3/2014 | Jonathan T Md Lord | Director | Buy | 101,163 | $2.39 | $241,779.57 | |
| 11/3/2014 | Larry N Feinberg | Major Shareholder | Buy | 2,067,979 | $2.39 | $4,942,469.81 | |
| 7/22/2014 | Alexander K Arrow | COO | Buy | 7,812 | $1.92 | $14,999.04 | |
| 7/22/2014 | Frederick D Furry | CFO | Buy | 13,020 | $1.92 | $24,998.40 | |
| 7/22/2014 | Jeffrey M Nugent | CEO | Buy | 52,083 | $1.92 | $99,999.36 | |
| 7/22/2014 | Paul N Clark | Director | Buy | 520,833 | $1.92 | $999,999.36 | |
| 7/18/2014 | Larry N Feinberg | Major Shareholder | Buy | 2,270,836 | $1.92 | $4,360,005.12 | |
| 2/12/2014 | Larry N Feinberg | Major Shareholder | Buy | 2,035,033 | $2.57 | $5,230,034.81 | |
| 1/31/2014 | Larry Feinberg | major shareholder | Buy | 30,798 | $2.45 | $75,455.10 | |
| 12/19/2013 | Larry Feinberg | major shareholder | Buy | 340,000 | $1.80 | $612,000.00 | |
| 12/17/2013 | Larry Feinberg | major shareholder | Buy | 150,400 | $1.87 | $281,248.00 | |
| 8/23/2012 | Frederick D Furry | CFO | Buy | 5,075 | $1.64 | $8,323.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Biolase (NASDAQ:BIOL)
Latest Headlines for Biolase (NASDAQ:BIOL)
| Source: |
|
| Date | Headline |
|---|
 | ETFs with exposure to BIOLASE, Inc. : September 6, 2017
finance.yahoo.com - September 5 at 11:15 PM |
| BIOLASE Names Jonathan T. Lord Chairman of the Board
finance.yahoo.com - September 5 at 6:10 PM |
 | LeMaitre Vascular (LMAT) and Biolase (BIOL) Head-To-Head Review
www.americanbankingnews.com - September 2 at 4:10 PM |
| ETFs with exposure to BIOLASE, Inc. : August 25, 2017
finance.yahoo.com - August 25 at 6:18 PM |
 | Globsl $10 Billion Dental Diagnostics & Surgical Equipments Products Markets, 2022
www.finanznachrichten.de - August 17 at 5:55 PM |
| BIOLASE, Inc. :BIOL-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017
finance.yahoo.com - August 16 at 5:05 PM |
 | Global Dental Diagnostics & Surgical Equipments Market, Company Analysis & Forecast to 2024
www.prnewswire.com - August 14 at 9:59 PM |
| Contrasting Dextera Surgical (DXTR) and Biolase (NASDAQ:BIOL)
www.americanbankingnews.com - August 11 at 3:08 PM |
| Edited Transcript of BIOL earnings conference call or presentation 7-Aug-17 8:30pm GMT
finance.yahoo.com - August 8 at 9:42 PM |
| ETFs with exposure to BIOLASE, Inc. : August 8, 2017
finance.yahoo.com - August 8 at 4:20 PM |
| Biolase, Inc. (BIOL) Releases Earnings Results, Misses Estimates By $0.04 EPS
www.americanbankingnews.com - August 8 at 12:28 PM |
| Biolase reports 2Q loss
finance.yahoo.com - August 7 at 10:05 PM |
| BIOLASE Reports 2017 Second Quarter and Six-Month Results
finance.yahoo.com - August 7 at 5:04 PM |
| Biolase (NASDAQ:BIOL) & Agilent Technologies (A) Head-To-Head Comparison
www.americanbankingnews.com - August 2 at 8:10 AM |
| BIOLASE® to Host 2017 Second Quarter Financial Results Conference Call on August 7
finance.yahoo.com - July 31 at 4:34 PM |
 | BRIEF-Biolase Inc files for resale of up to 12 million shares
www.reuters.com - July 22 at 9:30 PM |
| ETFs with exposure to BIOLASE, Inc. : July 13, 2017
finance.yahoo.com - July 13 at 5:34 PM |
 | Form 4 BIOLASE, INC For: Jun 30 Filed by: MOLL FREDERIC H
www.streetinsider.com - July 4 at 8:26 PM |
| Form 4 BIOLASE, INC For: Jun 30 Filed by: CLARK PAUL N
www.streetinsider.com - July 4 at 2:43 AM |
| ETFs with exposure to BIOLASE, Inc. : June 26, 2017
finance.yahoo.com - June 26 at 4:31 PM |
| Medical Lasers Market Size is Projected to be Around $13 Billion by 2025: Crystal Market Research
www.prnewswire.com - June 20 at 4:38 PM |
 | BIOLASE (BIOL) Presents At 7th Annual LD Micro Invitational Conference - Slideshow
seekingalpha.com - June 8 at 4:44 PM |
| Reviewing EnteroMedics (ETRM) and BIOLASE (BIOL)
www.americanbankingnews.com - June 6 at 2:06 PM |
| BIOLASE to Present at the 7th Annual LD Micro Invitational
finance.yahoo.com - May 31 at 10:35 AM |
| ETFs with exposure to BIOLASE, Inc. : May 22, 2017
finance.yahoo.com - May 22 at 3:52 PM |
| Short Interest in BIOLASE Inc (BIOL) Drops By 1.4%
www.americanbankingnews.com - May 13 at 7:08 PM |
| ETFs with exposure to BIOLASE, Inc. : May 11, 2017
finance.yahoo.com - May 11 at 4:28 PM |
| BIOLASE, Inc. :BIOL-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017
finance.yahoo.com - May 9 at 3:56 PM |
| BIOLASE Announces Management Change
finance.yahoo.com - May 5 at 3:56 PM |
| BIOLASE Inc (BIOL) Posts Quarterly Earnings Results, Misses Estimates By $0.03 EPS
www.americanbankingnews.com - May 4 at 9:00 PM |
| Edited Transcript of BIOL earnings conference call or presentation 3-May-17 8:30pm GMT
finance.yahoo.com - May 4 at 4:03 PM |
| BIOLASE Reports 2017 First Quarter Results
finance.yahoo.com - May 3 at 6:14 PM |
 | Biolase reports 1Q loss
marketbeat.com - May 3 at 6:05 PM |
| Somewhat Favorable Media Coverage Somewhat Likely to Impact BIOLASE (BIOL) Share Price
www.americanbankingnews.com - May 2 at 11:26 PM |
| BIOLASE Inc (BIOL) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - May 1 at 1:18 PM |
| BIOLASE (BIOL) Earning Somewhat Favorable News Coverage, Report Finds
www.americanbankingnews.com - April 26 at 2:32 PM |
| BIOLASE® to Host 2017 First Quarter Financial Results Conference Call on May 3
finance.yahoo.com - April 26 at 12:27 PM |
| BIOLASE Inc (BIOL) Coverage Initiated at Singular Research
www.americanbankingnews.com - April 25 at 3:06 PM |
| Form 4 BIOLASE, INC For: Apr 18 Filed by: LORD JONATHAN T MD
www.streetinsider.com - April 19 at 9:14 PM |
| BIOLASE (BIOL) Earning Somewhat Favorable Media Coverage, Report Finds
www.americanbankingnews.com - April 17 at 5:25 PM |
| BIOLASE (BIOL) Earning Positive News Coverage, Report Shows
www.americanbankingnews.com - April 14 at 5:40 PM |
| BIOLASE to Raise $10.5 Million from Institutional and Individual Investors in a Private Placement
finance.yahoo.com - April 13 at 4:03 PM |
 | REGISTER TODAY: Multidisciplinary Treatment Solutions for Peri-Implantitis Symposium
www.bizjournals.com - April 7 at 3:52 PM |
 | BIOLASE to Showcase Two New Game-Changing Products at International Dental Show in Cologne
uk.finance.yahoo.com - March 20 at 11:08 AM |
| BIOLASE, INC Financials
finance.yahoo.com - March 16 at 3:22 PM |
| BIOLASE Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - March 14 at 8:41 AM |
| BIOLASE Names James D. Surek Vice President Sales, Americas
finance.yahoo.com - March 13 at 11:12 AM |
| BIOLASE, INC Files SEC form 10-K, Annual Report
biz.yahoo.com - March 10 at 4:44 PM |
| BIOLASE to Present at the 29th Annual ROTH Conference
finance.yahoo.com - March 9 at 4:27 PM |
| BRIEF-Biolase Q4 loss per share $0.07
www.reuters.com - March 9 at 2:42 AM |
Biolase (BIOL) Chart for Thursday, September, 21, 2017
